

Global Anal Cancer Drugs and Companies Pipeline Review H2 2016

Anal Cancer Treatment Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- Summary

'[Anal Cancer](#) - Pipeline Review, H2 2016', provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/643481->

[anal-cancer-pipeline-review-h2-2016](https://www.wiseguyreports.com/reports/643481-anal-cancer-pipeline-review-h2-2016)

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/643481-anal-cancer-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research



institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/643481-anal-cancer-pipeline-review-h2-2016>

Key Points in Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anal Cancer Overview 7

Therapeutics Development 8

Pipeline Products for Anal Cancer - Overview 8

Pipeline Products for Anal Cancer - Comparative Analysis 9

Anal Cancer - Therapeutics under Development by Companies 10

Anal Cancer - Therapeutics under Investigation by Universities/Institutes 11

Anal Cancer - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Anal Cancer - Products under Development by Companies 14

Anal Cancer - Products under Investigation by Universities/Institutes 15

Anal Cancer - Companies Involved in Therapeutics Development 16

Advaxis, Inc. 16

Amgen Inc. 17
Cell Medica Limited 18
Eli Lilly and Company 19
GenticeL S.A. 20
ISA Pharmaceuticals B.V. 21
Novartis AG 22
Ono Pharmaceutical Co., Ltd. 23
Oryx GmbH & Co. KG 24
PDS Biotechnology Corporation 25
Sun Pharma Advanced Research Company Ltd. 26
Taiwan Liposome Company, Ltd. 27
Anal Cancer - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
axalimogene filolisbac - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
CMD-004 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
GTL-001 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ISA-101 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
nivolumab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
paclitaxel albumin free - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
panitumumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
PDR-001 - Drug Profile 95
Product Description 95

Mechanism Of Action 95
R&D Progress 95
PDS-0101A - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
prexasertib - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
TLC-388 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Vicoryx - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643481

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.